Cargando…

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR ‐mutated non‐small‐cell lung cancer: A case report

A therapeutic option for advanced non‐small‐cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) resistance is a clinical challenge. The clinical outcomes of pembrolizumab in those patients is inconclusive. Cytokine release syndrome (CRS) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Meng, Cheng, Yuan, Hu, Yan, Nie, Ligong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058301/ https://www.ncbi.nlm.nih.gov/pubmed/35384319 http://dx.doi.org/10.1111/1759-7714.14390

Ejemplares similares

Pembrolizumab and chemotherapy in non‐small cell lung cancer with EGFR ex20ins mutation: A case report
por: Zhang, Meng, et al.
Publicado: (2021)

Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report
por: Taniguchi, Yuri, et al.
Publicado: (2019)

Pembrolizumab: Cytokine release syndrome and haemophagocytic lymphohistiocytosis : case report
Publicado: (2021)

Cytokine release syndrome induced by pembrolizumab: A case report
por: Zhang, Xinyu, et al.
Publicado: (2022)

Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report
por: Sackstein, Paul, et al.
Publicado: (2021)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab
por: Taki, Takahiro, et al.
Publicado: (2020)

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
por: ZHOU, BO, et al.
Publicado: (2016)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
por: Cheng, Yuan, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
por: Cheng, Yuan, et al.
Publicado: (2019)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer
por: Hammoudeh, ZA, et al.
Publicado: (2018)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
por: Belani, Neel, et al.
Publicado: (2023)

Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer
por: Yomota, Makiko, et al.
Publicado: (2021)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
por: Ali, Azhar, et al.
Publicado: (2018)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report
por: Nakano, Yuta, et al.
Publicado: (2020)

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
por: Shi, Yuankai, et al.
Publicado: (2015)

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer
por: Hu, Wentao, et al.
Publicado: (2017)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab
por: Hatayama, Tomoya, et al.
Publicado: (2020)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
por: Field, Matthew G., et al.
Publicado: (2022)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Role of Cytokines Released During Pyroptosis in Non-Small Cell Lung Cancer
por: Huang, Yuanli, et al.
Publicado: (2021)

Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
por: Nomura, Masaharu, et al.
Publicado: (2007)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_33rf3mqibgkrucgg5gmi3iskoj